MDACC Study No:2003-0578 ( NCT No: NCT01159028)
Title:A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Principal Investigator:Maro Ohanian
Treatment Agent:L-Grb-2 Antisense Oligonucleotide
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest safe dose of
BP1001 , a liposomal Growth Factor Receptor Bound Protein-2 antisense
oligodeoxynucleotide (L-Grb2 AS), that can be given as treatment for patients
with Ph+ CML, AML, ALL, or MDS. BP1001 is an antisense drug, which means it may
help stop cancer cells by blocking the action of a protein that signals cancer
cells to divide and increase in number. The protein that BP1001 blocks is
called Grb-2. The response of the leukemia to this treatment will also be
studied. In addition, the time needed for the body to process this drug will
be evaluated.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:L-Grb-2 Antisense Oligonucleotide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No hospitalizations are expected.
Supported By:N/A
Return Visit:Patients must return to clinic twice weekly.
Home Care:All treatment will be administered at M.D. Anderson Cancer Center in the
Clinical and Translational Research Center.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Maro Ohanian
For Clinical Trial Enrollment:713-792-2631
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults